Table 1.
Patient characteristics (all patients)
| Characteristic | N = 66 |
|---|---|
| Age (years) | |
| Median (min, max) | 53 (32-79) |
| Sex | |
| Male | 32 (48%) |
| Female | 34 (52%) |
| Performance score | |
| ECOG/Zubrod = 0 | 49 (74%) |
| ECOG/Zubrod = 1 | 17 (26%) |
| Stage | |
| Bulky stage 2 | 5 (8%) |
| Stage 3 | 27 (41%) |
| Stage 4 | 34 (51%) |
| B-symptoms | |
| No | 59 (89%) |
| Yes | 5 (8%) |
| Unknown/not reported | 2 (3%) |
| Grade | |
| Grade 1 | 39 (59%) |
| Grade 2 | 21 (31.8%) |
| Grade 3a | 4 (6%) |
| Unknown/not reported | 2 (3%) |
| Number of nodal sites | |
| ≤4 | 33 (50%) |
| >4 | 33 (50%) |
| FLIPI risk | |
| Low | 21 (32%) |
| Intermediate/higha | 45 (68%) |
| Bulky diseaseb | |
| No | 50 (76%) |
| Yes | 15 (23%) |
| Unknown | 1 (1%) |
| FcgR polymorphismc | |
| FCGR3A 158F | 22 (37%) |
| FCGR3A 158 F/V | 27 (46%) |
| FCGR3A 158V | 10 (17%) |
| FCGR2A 131H | 18 (31%) |
| FCGR2A 131 R/H | 28 (47%) |
| FCGR2A 131R | 13 (22%) |
a
Two patients had FLIPI score > 2; following are their risk factors: age > 60 years, FL-Bulky stage 2, WHO class grade 3a, Hb > 12 and age > 60 years, FL-stage 4, >4 nodal sites.
b
Of patients with bulky disease, five were Bulky stage 2, three were stage 3 and seven were stage 4; unknown was stage 3.
c
Fifty-nine consented patients with FcgR results.